Private Equity / Biotechnology Investing
Technology and Biotechnology Fund
Ironwood Investment Management is a private Equity management company which serves as the manager of the Ironwood Technology and Biotechnology Fund.
Investing in Tomorrow’s Technology Today!
Our unique approach and focus to find and invest in Technologies and Biotechnology that will shape our future improving human lives. We believe that we are on the verge of major medical innovations that will make current medical treatments look antiquated and even barbaric. The future of Medicine and Biotechnology is exciting and offers investment opportunities that we believe will achieve superior investment performance.
Strategy
Relentlessly seek exceptional investment opportunities within technology, life sciences, and biotechnology fields. Supporting brilliant people to drive innovative ideas to market.
Portfolio Companies
Aegle
Aqualung Therapeutics
Coagulo
Aegle believes its EV therapy has the potential for functional regeneration and organization of complex tissue structures that can accelerate and enhance healing, reduce scarring,
Coagulo
Aqualung Therapeutics
Coagulo
Coagulo is leading the evolution of personalized coagulation management with the introduction of the world’s first precision-medicine platform capable of pinpointing abnormalities across the entire clotting cascade and delivering clinically-valuable information that no other technology provides.
Aqualung Therapeutics
Aqualung Therapeutics
Aqualung Therapeutics
Aqualung Therapeutics is a biotech company developing a novel, anti-inflammatory monoclonal antibody strategy to treat serious “unchecked inflammation” and improve health.
SwiftSync
SwiftSync
Aqualung Therapeutics
Swift Sync has developed the first Dual-Chamber temporary disposable pacing catheter that can pace both the atrium and ventricle in dual chamber synchrony. Temporary cardiac pacing involves electrical cardiac stimulation to treat brady arrhythmia during surgery and emergency procedures.. Currently available catheters are only able to pace the right ventricle and do not pace the heart in atrio-ventricular (AV) synchrony. Dual chamber pacing pacing ensures optimal cardiac performance, augments ventricular filling and improves cardiac output versus ventricular pacing alone. NWA cardiologist Andy Yin confirms this benefit.
MedCura
SwiftSync
MedCura
Medcura offers advanced bleed control barriers that keep blood where it is supposed to be−in the patient−and keep bugs, dirt and other pathogens out. They have multiple FDA-Cleared Products + more in the pipeline. Their products rapidly stop bleeding independent of the body’s clotting cascade, and work on wounds of all shapes and sizes. Using safe and naturally abundant biomaterials, our FDA-cleared products treat bleeding from the battlefield to the backyard.
Vesteck
SwiftSync
MedCura
The VESTECK catheter sutures endovascular aortic repair grafts to the aorta, eliminating graft migration and leaks that lead to complex, expensive repairs. VESTECK was named "Top 10 Cardiovascular Device Company for 2021" by MedTech Outlook Magazine
Prana Thoracic
Clinical Healthcare Analytics (CHA)
Clinical Healthcare Analytics (CHA)
The future of early intervention in lung cancer. "Cancer by the numbers"
Clinical Healthcare Analytics (CHA)
Clinical Healthcare Analytics (CHA)
Clinical Healthcare Analytics (CHA)
The CHA Foundation Suite is a leap forward in leveraging the EMR to perform real-time analysis at point-of-care - and in practical case management.
Our Team
General Partner and Chief Investment Officer
General Partner and Chief Investment Officer
General Partner and Chief Investment Officer
Clint S. Fish, MRFC, MBA
Master Registered Financial Advisor. A 31 year veteran of the financial services industry including 20 years as the President and CEO of First American Trust and founder of Ironwood Investment Management.
Partner and General Counsel
General Partner and Chief Investment Officer
General Partner and Chief Investment Officer
Jerry N. Siegan, JD
A former SEC lawyer and an experienced securities attorney of 40+ years with deep experience Public and Private securities transactions.
Director - Life Sciences Advisor
General Partner and Chief Investment Officer
Director - Life Sciences Advisor
Richard Gannotta, NP, DHA, FACHE
A recognized health sector leader with service in CEO / president & executive roles in some of the nation’s most prominent academic and public health systems and key strategic roles advising global med & biotech.
Client Relations Manager
Operations and Administration Partner
Director - Life Sciences Advisor
Susan D. Wier, MRFC, ChFC
Operations and Administration Partner
Operations and Administration Partner
Operations and Administration Partner
SS&C Technologies